Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NYSE American:CANF) traded at a new 52-week high today of $2.98. This new high was reached on above average trading volume as 10.5 million shares traded hands, while the average 30-day volume is approximately 1.1 million shares.
There is potential upside of 244.1% for shares of Can-Fite Biopharma Ltd Sponsored ADR (Israel) based on a current price of $2.78 and an average consensus analyst price target of $9.57.
Can Fite Biofarma Ltd is a clinical-stage biopharmaceutical company. The company is focused on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune inflammatory indications, oncology and liver diseases as well as sexual dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention. The company’s pipeline drugs are synthetic, specific agonists and allosteric modulators targeting the A3AR. All drugs are orally bioavailable with an excellent safety profile.
Can-Fite Biopharma Ltd Sponsored ADR (Israel) share prices have moved between a 52-week high of $2.98 and a 52-week low of $1.10 and are now trading 153% above that low price at $2.78 per share.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer